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Abstract
Objective
To provide detailed long-term outcome data of children and adolescents following pediatric anti-
N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis, to identify neuropsychological
impairments, and to evaluate the inﬂuence of these factors on quality of life (QoL).
Methods
All Dutch children diagnosed with anti-NMDAR encephalitis were identiﬁed. Patients cur-
rently aged 4 years or older were included in the follow-up study, consisting of a visit to our
clinic for a detailed interview and a standardized neuropsychological assessment. The following
domains were included: attention, memory, language, executive functioning, QoL, and fatigue.
Primary outcome measures were z scores on sustained attention, long-term verbal memory,
QoL, fatigue, and working memory.
Results
Twenty-eight patients were included. Median Pediatric Cerebral Performance Category at last
visit was 1 (interquartile range 1–2, range 1–4), and 64% (18/28) of patients returned con-
sistently to their previous school level. Twenty-two patients were included in the cross-sectional
part of the long-term follow-up study. Median follow-up time was 31 months (interquartile
range 15–49, range 5–91). There were problems with sustained attention (z = −2.10, 95%
conﬁdence interval = −2.71 to −1.46, p < 0.0001) and fatigue (z = −0.96, 95% conﬁdence
interval = −1.64 to −0.28, p = 0.008). Cognitive deﬁcits were not correlated with QoL, while
fatigue was strongly correlated with QoL (r = 0.82, p < 0.0001).
Conclusions
Although follow-up is often reported as “good” following pediatric anti-NMDAR encephalitis,
many patients have cognitive problems and fatigue, even up until adolescence, resulting in
academic achievement problems and lower QoL. For physicians, it is essential to be aware of
these problems, to provide valuable advice to patients and caregivers in the acute and follow-up
phase, and to consider early neuropsychological counseling.
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Anti-N-methyl-D-aspartate receptor (anti-NMDAR) enceph-
alitis is an autoimmune disorder, initially described in 2007.1
Increased awareness has led to more frequent diagnoses, and
currently more than 1,000 patients have been reported, of
whom 35% are children.2 The disease course can be severe,
with intensive care unit (ICU) admission in 75% of children.
Nevertheless, if treated with adequate immunotherapy, out-
come is considered favorable in 85% of children.2
However, there are signals that actual recovery might be less
positive than initially reported. Small studies in both adults
and children describe substantial deﬁcits in multiple cognitive
domains and also behavioral problems.3–9 Given these ﬁnd-
ings, it seems that despite apparent good outcome, full neu-
ropsychological recovery is certainly not always achieved.
Functioning can be studied from diﬀerent perspectives,10 in-
cluding activities and participation. Outcome of anti-NMDAR
encephalitis is currently measured in terms of activities with
relatively crude measures, such as the modiﬁed Rankin Scale
(mRS),11 while participation and quality of life (QoL) are also
of major importance, especially in children and adolescents.
Neuropsychological deﬁcits can seriously aﬀect participation
and career choices as transition into adulthood might call for
full cognitive abilities.
Therefore, the aim of this nationwide Dutch cohort study was
to provide more insight into long-term outcome following
pediatric anti-NMDAR encephalitis, with special emphasis on
neuropsychological outcome, and to evaluate whether these
neuropsychological factors inﬂuence QoL.
Methods
Patients
The Departments of Neurology and Pediatric Neurology of
the Erasmus University Medical Center–Sophia Children’s
Hospital, Rotterdam, the Netherlands, are national referral
sites for patients with suspected autoimmune encephalitis. In
addition, the Department of Immunology is the national re-
ferral site for antineuronal antibody testing of samples from
patients with suspected autoimmune encephalitis. Therefore,
we had the opportunity to identify all Dutch children di-
agnosed with anti-NMDAR encephalitis, from January 2008
until March 2017, aged 0 to 18 years at disease onset.
NMDAR antibodies were conﬁrmed in serum and/or CSF by
both commercial cell-based assay and immunohistochemistry.
Clinical information
Data about disease course were obtained from medical
records and from detailed interviews with patients and care-
givers during a visit to our clinic. Neurologic level of function
was determined using the Pediatric Cerebral Performance
Category (PCPC) scale (table e-1, links.lww.com/WNL/
A495).12
Standard protocol approvals, registrations,
and patient consents
The institutional review board of the Erasmus University
Medical Center approved the study protocol. Informed con-
sent was obtained from adult patients and for children from
their parents, and if applicable, also from children aged 12 to
18 years.
Cross-sectional follow-up study
All patients currently aged 4 years or older were approached
to participate in the follow-up study, as neuropsychological
testing and the questionnaires required a minimal age for
participation. Patients were invited for a visit to our clinic, in
which current complaints and level of functioning were dis-
cussed. In addition, patients underwent a standardized neu-
ropsychological assessment. If a visit was not possible, current
problems were discussed by phone, and questionnaires were
sent to us by mail and checked in additional calls if necessary.
Neuropsychological assessment
The neuropsychological assessment consisted of a selection of
the Cambridge Neuropsychological Test Automated Battery
(CANTAB Research Suite 6.0, Cambridge Cognition Ltd.,
Cambridge, UK), additional neuropsychological tests, and
questionnaires (table e-2, links.lww.com/WNL/A495). Tests
and questionnaires were selected based on our own experi-
ences and on disorders found in prior studies, were admin-
istrated in their Dutch versions, and are reliable and validated
in the Netherlands. The tests and questionnaires were ad-
ministered to assess skills in 6 domains:
1. Attention: Reaction Time (CANTAB), Dutch Dot
Cancellation Test (Bourdon-Vos).13
2. Memory: Paired Associated Learning (CANTAB), Rey
Auditory Verbal Learning Test (RAVLT).14
3. Language: Boston Naming Test,15 Token Test.16
4. Executive functioning: Intra-Extra Dimensional Set Shift,
Spatial Span, Stockings of Cambridge (all CANTAB),
Word Generation (NEPSY-II [ A Developmental Neuro-
psychological Assessment, Second Edition]),17 Behavior
Glossary
anti-NMDAR = anti-N-methyl-d-aspartate receptor; BRIEF = Behavior Rating Inventory of Executive Function; CANTAB =
Cambridge Neuropsychological Test Automated Battery; HSV = herpes simplex virus; ICU = intensive care unit; IQR =
interquartile range;mRS =modiﬁed Rankin Scale; PedsQL = Pediatric Quality of Life; PedsQL-MFS = Pediatric Quality of Life
Multidimensional Fatigue Scale; PCPC = Pediatric Cerebral Performance Category; QoL = quality of life; RAVLT = Rey
Auditory Verbal Learning Test.
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Rating Inventory of Executive Function (BRIEF–Self-
Report and BRIEF–Adult) questionnaire,18 Strength and
Diﬃculties Questionnaire (self-report and parent-proxy
report).19
5. QoL: Pediatric Quality of Life Inventory 4.0 (PedsQL
Self-Report and PedsQL Parent Proxy-Report).20
6. Fatigue: PedsQL Multidimensional Fatigue Scale ques-
tionnaire (PedsQL-MFS Self-Report and PedsQL-MFS
Parent Proxy-Report).21
Statistical analysis
For group comparisons, we used the Mann-Whitney U test
(age), Fisher exact test (sex, immunotherapy), Fisher-
Freeman-Halton extension (PCPC), and the Kruskal-Wallis
one-way analysis of variance (character proﬁles). Results of
neuropsychological assessments were compared with nor-
mative data of healthy individuals, corrected for age, sex, and
educational level. Normative data for the CANTAB were
obtained by CANTAB, Cambridge, UK. Scores were con-
verted into standardized z scores for comparison. For statis-
tics, z scores were set on minimum of −3 and maximum of +3
to prevent statistical diﬀerences by outliers (winsorization). In
the graphs, the uncorrected z scores are shown, but corrected
z scores were used for statistics. Displayed correlations were
also calculated with corrected z scores. The z scores were
analyzed using a one-sample t test (test value = 0). Primary
outcome measures were sustained attention (Dutch Dot
Cancellation Test–attention ﬂuctuations), long-term verbal
memory (RAVLT–Delayed Recall), fatigue (PedsQL-MFS
Self-Report–Total Score), QoL (PedsQL Self-Report–Total
Score), and working memory (BRIEF–Self-Report–Working
Memory). Primary outcome measures were considered sig-
niﬁcant if p < 0.017 (Bonferroni). For the secondary outcome
measures of the neuropsychological assessment, p values
<0.005 were considered signiﬁcant. Values between 0.005 and
0.05 should be interpreted carefully and considered explor-
atory. The relationship between our primary outcome meas-
ures and QoL were computed with a two-sided Pearson
correlation coeﬃcient. SPSS version 21.0 (IBM Corp.,
Armonk, NY) was used for statistical analyses, as well as
GraphPad Prism 7 (GraphPad Software, La Jolla, CA) for
Windows.
Data availability
Any data not published within this article are available at
Erasmus University Medical Center. Patient-related data will
be shared on request from any qualiﬁed investigator, main-
taining anonymization of the individual patients.
Results
Clinical characteristics
Thirty children were identiﬁed, of whom 28 were included
(for patient selection, see ﬁgure 1). Twenty-one patients were
female (75%), mainly in those aged 12 years or older (89%).
Median age at onset was 14 years. Eighteen patients (64%)
reported a prodromal phase, including headache, blurred
vision, or upper respiratory infection. Three children (11%)
developed anti-NMDAR encephalitis 3 to 7 weeks after
a herpes simplex virus (HSV) type 1 encephalitis. In addition
to those 3, one patient had a preexistent mild psychomotor
developmental delay. The others were healthy before disease
onset.
Most children presented with behavioral disorders (36%) or
seizures (36%), less frequently with speech disorders and
movement disorders. In 2 of 28 patients (7%), hemiparesis
was the presenting symptom, only occurring in children
younger than 12 years (ﬁgure 2A). All patients presented to
the initial physician with a maximum of 3 symptoms, while at
maximum disease severity, 21 patients had developed more
than 4 symptoms (ﬁgure 2, B and C). The numbers of
symptoms between treatment and diagnosis were often
comparable. Four patients developed one additional symp-
tom after start of treatment, i.e., hypoventilation (n = 3) and
bradycardia (n = 1). One patient developed seizures after
diagnosis but before treatment, with a delay between di-
agnosis and treatment of 2 days (patient 16). One patient
developed seizures 3 days after diagnosis and 9 days after
initiation of treatment (patient 9).
Median time from symptom onset to maximum PCPC
(maximum disease severity) was 30 days. Forty-six percent of
patients (13/28) were treated in the ICU with a median stay
of 13 days. Total hospital stay was more than a month in 78%
of patients. All patients were treated with ﬁrst-line immuno-
therapy. Forty-six percent of patients received either
Figure 1 Flowchart of patient selection
One patient was excluded because he was younger than 4 years (trans-
placental transmission of anti-N-methyl-D-aspartate receptor),31 and one
patient was untraceable. Twenty-four patients participated in the follow-up
study, of whom 2 are followed prospectively. Sixteen of the 22 participants
completed the full neuropsychological assessment, 6 patients only com-
pleted the questionnaires, 3 visited our clinic, and 3 were contacted by
phone because of geographical distance. NPT = neuropsychological testing.
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rituximab (n = 12) or cyclophosphamide (n = 1). In 14 of 28
patients (50%), treatment was started before diagnosis, in 6 of
28 patients (21%), treatment was initiated on the day of di-
agnosis, and in 8 of 28 patients (29%), treatment was started
after diagnosis. For all clinical characteristics, see table 1 and
supplemental material (links.lww.com/WNL/A493).
Outcome
Three patients had a relapse 3, 5, and 35 months after ﬁrst
symptoms. One patient had a higher PCPC during the relapse
than during the initial disease episode, leading to the initiation
of rituximab. At hospital discharge, the median PCPC was 3
(interquartile range [IQR] 2–3, range 1–4). Seventeen
patients were discharged home, although 10 concurrently
started with an outpatient rehabilitation program. Eleven
patients (39%) were transferred directly to an inpatient re-
habilitation center. Median rehabilitation time was 98 days
(IQR 58–194, range 34–578). The median PCPC at last visit
was 1 (IQR 1–2, range 1–4). Twenty-six patients (93%) re-
sumed school after admission or rehabilitation. In 6 of the 26
patients (23%) who resumed school, the current educational
level was lower, including 5 patients with special educational
needs. During follow-up, 3 patients stopped school pre-
maturely because of fatigue (n = 2) or anxiety (n = 1). Overall,
Figure 2 Patient symptoms
(A) Distribution of presenting symptoms of patients younger than 12 years and of patients aged 12–18 years. (B) Cumulative symptoms during disease course.
(C) Number of core symptoms at presentation, treatment, and antibody diagnosis, and total number of symptoms.
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18 of 28 patients (64%) returned consistently to their pre-
vious school level.
Cross-sectional follow-up study
Twenty-two patients participated in the follow-up study, with
a median follow-up time after symptom onset of 31 months
(IQR 15–49, range 5–91). Nineteen were seen at our clinic,
while 3 had an interview by phone. All 22 patients completed
questionnaires, while 16 patients completed the full neuro-
psychological assessment (ﬁgure 1). Individual information is
shown online in table e-3 (links.lww.com/WNL/A495).
Median age at last visit was 17 years (IQR 12–19, range 4–25).
Three patients had post-HSV encephalitis anti-NMDAR en-
cephalitis, 2 with a follow-up PCPC of 3 (patients 14 and 18)
and 1 with a PCPC of 4 (patient 19). One patient had a PCPC
of 4 because of spasticity and vocal cord paralysis (patient 6).
Neuropsychological outcome
Characteristics of the 16 patients who underwent full neu-
ropsychological assessment were similar to those of the other
patients (n = 13; table e-4, links.lww.com/WNL/A495).
Patients had lower sustained attention scores (z = −2.10,
puncorrected < 0.0001; table 2), and these were consistent
among almost all patients. The mean score on long-term
verbal memory tended to be lower (z = −0.68, puncorrected =
0.031). Patients reported more fatigue (z = −0.96, puncorrected
= 0.008), andQoL tended to be lower (z = −0.87, puncorrected =
0.032), while working memory was not diﬀerent (z = 0.24,
puncorrected = 0.23). Results were similar when the 3 patients
with anti-NMDAR encephalitis post HSV encephalitis were
excluded (1 full neuropsychological assessment, 2 only
completed questionnaires; data not shown).
There was a strong correlation between self-reported fatigue
and QoL (r = 0.82, p < 0.0001; ﬁgure 3), also as reported by
parents (Parent Proxy-Report−Total Score; r = 0.70, p =
0.004). There were no signiﬁcant correlations between QoL
and fatigue and the cognitive domains sustained attention and
long-term verbal memory (ﬁgure 3). Treatment delay, follow-
up time, age at onset, ICU stay, maximum PCPC, and PCPC
at follow-up were not correlated with sustained attention,
long-term verbal memory, or fatigue (ﬁgure e-1, links.lww.
com/WNL/A494). Sustained attention and long-term verbal
memory were also not correlated with QoL scores as reported
by parents (sustained attention: r = 0.20, p = 0.62; long-term
verbal memory: r = 0.45, p = 0.27).
Among the secondary outcome measures (tables e-5 and e-6,
links.lww.com/WNL/A495), the mean z score on domain
speed was lower (Dutch Dot Cancellation Test−reaction
time; z = −1.53, puncorrected = 0.002). Scores on the domains
visual memory (Paired Associated Learning−total errors; z =
−0.90, puncorrected = 0.016), short-term verbal memory
(RAVLT Trials 1–5); z = −0.76, puncorrected = 0.023),
and naming (Boston Naming Test−total score; z = −0.78,
puncorrected = 0.019) were low, but between 0.05 and 0.005.
Results of the questionnaires completed by parents were
comparable to those of children (table e-7, links.lww.com/
WNL/A495).
Patients and parents mentioned similar diﬃculties in the de-
tailed interview (17/22). Regarding school or work perfor-
mance, themost notable problemswere word ﬁnding diﬃculties
(24%), dyslexia (12%), and attention and concentration deﬁcits
Table 1 Patient characteristics
Sex, female 21/28 (75)
Age <12 y 4/9 (44)
Age ≥12 y 17/19 (89)
Age at onset, y 14 (7–17; 1–17)
Prodromal phase 18/28 (64)
Days to start of treatment 21 (9–65; 3–510)
Days to antibody diagnosis 27 (13–61; 13–184)
Days to maximum disease severity 30 (15–43; 2–94)
Maximum PCPC
3: Moderate disability 1/28 (4)
4: Severe disability 16/28 (57)
5: Coma/vegetative state 11/28 (39)
ICU stay, d 13 (4–34; 1–45)
Hospital stay, d 55 (33–67; 3–141)
MRI abnormala 10/27 (37)
CSF abnormala 21/27 (78)
EEG abnormal at presentationa 26/27 (96)
Ovarian teratoma suspected 4/21 (19)b
First-line IT 28/28 (100)
Methylprednisolone 27/28 (96)
Plasmapheresis 6/28 (21)
Immunoglobulins 21/28 (75)
Interval between first- and second-line IT, d 18 (14–41; 6–200)
Second-line IT 13/28 (46)
Rituximab 12/28 (43)
Cyclophosphamide 1/28 (4)
Cell-based assay anti-NMDAR seruma,c 16/24 (67)
Cell-based assay anti-NMDAR, CSFa 27/27 (100)
Abbreviations: anti-NMDAR = anti-N-methyl-D-aspartate receptor; ICU = in-
tensive care unit; IT = immunotherapy; PCPC = pediatric cerebral perfor-
mance category.
Data are n/n (%) or median (interquartile range; range).
a Additional details are shown online.
b For girls ≥12 years: 4/19 (21%). All 4 girls underwent resection; 3 had
a teratoma, one a follicle cyst.
c In one patient, only serum was available; cell-based assay, immunohisto-
chemistry, and live neurons were all positive.
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(18%). Other problems were impulsiveness (18%), anxiety
(18%), and indecisiveness (12%). Concerning the disease
period, 21 of 22 patients (95%) had a persistent (fragmented or
complete) amnesia.
Based on our own observations during the visits to our
clinics, we could diﬀerentiate 3 frontal lobe syndrome pro-
ﬁles using the character descriptions by parents and the
main complaints of the patients themselves. This way, we
allocated the patients visiting our clinic into 3 groups: (1)
passive (apathy, n = 5), (2) moderate (no signs of a frontal
lobe syndrome, n = 6), and (3) active (impulsive, n = 7).
The median scores on QoL and fatigue were compared
between these groups (visualized in ﬁgure e-2, links.lww.
com/WNL/A494). Among the passive patients, the school
dropout rate was 80% (4/5), while for the active patients,
school resumption was achieved in all 7, of whom 2 did not
retain previous school level.
Table 2 Results of primary outcome measures
Domain; test; measure No. z Score, mean 95% CI z Score <0, n (%) z Score <22, n (%) p Value
Sustained attention; DDCT; attention fluctuations 16 −2.10 −2.71 to −1.48 15 (94) 10 (63) <0.0001a
Long-term verbal memory; RAVLT–Delayed Recall 15b −0.68 −1.29 to −0.07 12 (80) 3 (20) 0.031
Fatigue; PedsQL-MFS; Self-Report; Total Score 21c −0.96 −1.64 to −0.28 16 (76) 5 (24) 0.008a
Quality of life; PedsQL; Self-Report; Total Score 21c −0.86 −1.64 to −0.08 15 (71) 7 (33) 0.032
Working memory; BRIEF; Working Memory 19c 0.24 −0.17 to 0.65 8 (42) 0 0.23
Abbreviations: BRIEF = Behavior Rating Inventory of Executive Function; CI = confidence interval; DDCT =Dutch Dot Cancellation Test;MFS =Multidimensional
Fatigue Scale; PedsQL = Pediatric Quality of Life; RAVLT = Rey Auditory Verbal Learning Test.
Exclusion of patient 6 (with vocal cord paralysis), patients 14, 18, and 19 (all post–herpes simplex virus encephalitis anti-N-methyl-D-aspartate receptor
encephalitis), and patient 16 (with prior mild developmental delay) did not affect results.
a p < 0.017 (Bonferroni).
b Of one patient (no. 6), no data are shown as the test was aborted because of vocal cord paralysis.
c No normative data available for test results of the youngest patient(s).
Figure 3 Overview of correlations between primary outcome measures
Outcome measures: sustained attention (Dutch Dot Cancellation Test–attention fluctuations), long-term verbal memory (RAVLT–Delayed Recall), fatigue
(PedsQL-MFS Self-Report–Total Score), QoL (PedsQL Self-Report–Total Score), and working memory (BRIEF–Working Memory). In all graphs, results of
uncorrected z scores are shown, but the correlations are calculated with corrected z scores (maximum 3, minimum −3). Anti-NMDAR = anti-N-methyl-D-
aspartate receptor; BRIEF = Behavior Rating Inventory of Executive Function; HSV = herpes simplex virus; LTM = long-term verbal memory; MFS = Multidi-
mensional Fatigue Scale; PedsQL = Pediatric Quality of Life; QoL = quality of life; RAVLT = Rey Auditory Verbal Learning Test.
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Discussion
We have demonstrated that, despite good functional recovery
(according to the mRS or PCPC), persistent cognitive deﬁcits
are common in young children and adolescents following
pediatric anti-NMDAR encephalitis, and that important
parameters for good outcome, such as treatment delay or
age at onset, do not speciﬁcally aﬀect neuropsychological
outcome. Other interesting and important ﬁndings are that
patients reported more fatigue, and that patients with fatigue
also reported a poorer QoL, while poorer cognitive outcome
did not aﬀect QoL.
Fatigue has not been evaluated before in patients with anti-
NMDAR encephalitis. However, it is known to be a common
disabling symptom in pediatric acquired brain injury,22,23
making our results that fatigue was associated with poorer
QoL plausible. This ﬁnding is supported further by the fre-
quent reporting of fatigue by patients as the most disabling
symptom often hampering normal participation.
Remarkably, poorer cognitive outcome did not inﬂuence
QoL, possibly because QoL questionnaires comprise general
topics, while patients often reported speciﬁc task-related
problems, which might be underestimated in current ques-
tionnaires. In addition, patients becoming accustomed to
a new “stable” situation and reduced awareness might be other
explanations. The latter is less likely because parents’ QoL
scores were comparable.
Predictors of good functional outcome such as treatment
delay, maximum PCPC, and ICU stay were not correlated
with QoL, fatigue, or sustained attention. This supports our
statement that “good” outcome certainly not always means
“good” total recovery. NMDAR antibodies are considered to
compromise signal transmission, leading to problems in
multiple functional networks, corresponding to the extent of
symptoms. Finke et al.24 showed that a reduced connectivity
of the anterior hippocampus and the anterior default mode
network was associated with poorer memory in anti-NMDAR
encephalitis.24 In addition, this reduced connectivity is also
described in a broad spectrum of other neurologic
conditions.25–28 These connections seem most vulnerable,
which may explain the discrepancy between good outcome
and poor memory recovery. A follow-up study testing patients
by serial neuropsychological tests combined with fMRI will be
essential to examine the correlation between cognitive func-
tioning and this reduced connectivity over time, and to ex-
amine whether this process is reversible.
Most anti-NMDAR encephalitis follow-up studies concen-
trate on the neurobehavioral problems of disinhibition.
However, frontal lobe syndromes are more widespread, and
little is known about passive patients during rehabilitation and
follow-up. Our data suggest that these “passive” patients
might be more at risk to develop problems with normal
participation because these patients showed more school
dropout rates and reported more fatigue. This observation
needs conﬁrmation in future research, but may have impor-
tant consequences for rehabilitation programs.
For cognitive outcome, we particularly observed lower scores
in the domain sustained attention and speed. Possibly these
cognitive deﬁcits are most prominent and should be consid-
ered during cognitive rehabilitation. However, there was no
correlation between the diﬀerent cognitive test results, which
underlines that the occurring cognitive deﬁcits are diverse and
probably diﬀerent parts of the brain are aﬀected. Short-term
verbal memory and language scores were also lower. Appar-
ently these domains are more vulnerable to dysfunction of the
NMDAR. These ﬁndings are partially in concordance with
earlier ﬁndings,3–9 although these previous published studies
describe more diverse cognitive deﬁcits, with additional def-
icits in executive functioning. However, these studies are
diﬃcult to interpret and to compare properly to our results
because of limited patient numbers and unstandardized
methods and because some patients were assessed in the acute
disease phase. By using standardized performance-based
measures, such as CANTAB, we found no prominent prob-
lems in executive functions. Nevertheless, by using rating
measures (questionnaires, interviews), patients reported
substantial diﬃculties in performing activities of daily living.
An explanation for this disconnection is that performance-
based measures and rating measures do not assess the same
aspects in cognitive and behavioral functioning. Rating
measures assess whether goals in activities of daily living are
reached and have higher ecological validity.29 Next to the
BRIEF (and other rating measures we performed), the BADS-
C (Behavioral Assessment of the Dysexecutive Syndrome in
Children) might be a useful addition.
The present study, with national coverage, detailed de-
scription of clinical data, and the use of a systematic neuro-
psychological assessment, provides broad, valuable results,
likely to be externally valid. This study exclusively pertains to
pediatric anti-NMDAR encephalitis, also a valuable aspect,
because in comparison to adults, there are diﬀerences in dis-
ease onset, treatment decisions, and social functioning. First,
children present more often with seizures or behavioral
changes,30 whereas adults mostly present with psychiatric
symptoms or memory dysfunction,2 which may lead to dif-
ferent intervals to diagnosis and treatment. Second, treatment
decisions can be age-dependent and may aﬀect outcome;
i.e., physicians tend to be more aggressive in children, starting
immunotherapy early while simultaneously being more
careful with cyclophosphamide. Third, neuropsychological
problems can seriously aﬀect participation as successful
transition into adulthood calls for full cognitive, emotional,
and behavioral abilities.
We had the unique opportunity to include all Dutch children
with anti-NMDAR encephalitis. Nevertheless, despite na-
tional coverage and increasing incidence, anti-NMDAR en-
cephalitis is a rare disease. Therefore, to include a suﬃcient
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number of patients with a reasonable follow-up time, a retro-
spective study design was inevitable but with the associated
problems. The ﬁrst issue is missing data. The amount of
missing data was minimized by contacting treating physicians,
parents, and patients. Regarding selection bias (between
patients participating and nonparticipating in the follow-up
study), we found no diﬀerence in clinical characteristics.
Furthermore, clinical characteristics are in line with previous
studies.2,30 The results of the participants thus seem to be
a good representation for the total group and results are
probably generalizable.
Overall, our ﬁndings highlight the importance of awareness
of persisting neuropsychological deﬁcits and excessive fatigue
following pediatric anti-NMDAR encephalitis. With a con-
siderable median follow-up time (almost 3 years), our results
clearly indicate that neuropsychological deﬁcits can be pro-
longed. Currently, disease outcome is assessed with param-
eters measuring impairment and disabilities (mRS,11 PCPC),
and treatment decisions are based on these parameters. Our
results show that neuropsychological parameters measuring
participation and QoL are also important and should be
considered when assessing outcome, because these factors
can substantially aﬀect participation and well-being. There-
fore, physicians should inform patients and parents correctly
about the occurrence of prolonged neuropsychological
problems. In addition, they should provide good accessibility
to neuropsychological counseling in rehabilitation centers
immediately following the acute disease course and during
follow-up.
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Study question
What are the long-term eﬀects of pediatric anti-NMDAR en-
cephalitis on neuropsychologic function and quality of life?
Summary answer
Many patients experienced cognitive problems and fatigue
even after apparent recovery, resulting in decreased quality of
life and impaired academic performance.
What is known and what this paper adds
Anti-NMDAR encephalitis is an autoimmune disorder, and the
disease course is severe in 75%of pediatric cases.While previous
studies have indicated good outcomes after immunotherapy,
new evidence suggests that negative long-term eﬀects may exist.
The present study conﬁrms these ﬁndings, and provides strong
evidence demonstrating the long-term eﬀects of pediatric anti-
NMDAR encephalitis. It suggests that academic performance is
most aﬀected by passivity as a sign of frontal lobe syndrome.
Participants and setting
Dutch children (0–18 years of age; n = 28) diagnosed with
anti-NMDAR encephalitis between January 2008 and March
2017 were included in the initial study. Of these, 22 patients
were included in the cross-sectional study.
Design, size, and duration
Clinical information was extracted from medical records and
detailed clinical interviews. Outcome data were obtained during
a cross-sectional follow-up phase in which participants com-
pleted an in-clinic standardized neuropsychologic assessment or
a mailed questionnaire and telephone interview. Neuro-
psychologic results were converted into standardized z score and
compared to normative data for healthy matched subjects.
Primary outcomes
Patient functioning was assessed using z scores in 5 domains:
sustained attention, long-term verbal memory, working mem-
ory, quality of life, and fatigue.
Main results and the role of chance
The children were predominantly female (75%) and ≥12 years
of age (89%). The median age of onset was 14 years. Sixty-four
percent of patients returned to their previous school level.
Sixteen children completed the neuropsychological assessment
and showed impairments in sustained attention (z = −2.10,
95% CI = −2.71 to −1.46, p < 0.0001) and fatigue (z = −0.96,
95%CI = −1.64 to −0.28, p = 0.008). Fatigue, but not cognitive
function, was strongly correlated with quality of life (r = 0.82,
p < 0.0001).
Bias, confounding, and other reasons
for caution
The study included a small number of patients, especially in
the cross-sectional phase.
Generalizability to other populations
The results can be generalized to other cases of pediatric anti-
NMDAR encephalitis.
Study funding/potential competing interests
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